Fundraising FoxRoche Venture Fund — 2015 Investments
3 investments dated 2015 · listed companies and verified rows first · show all
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+15 more
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersYsios Capital+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.